UNSPSC 51112302: Improsulfan

This classification denotes an alkylsulfonate compound with the molecular formula C8H19NO6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32Y1F7N1ZD, chemically known as 3,3-iminodi-1-propanol dimethanesulfonate (ester) but more generally known as improsulfan, which bears US NIH Compound Identifier 18949. European Medicines Agency schedules Improsulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08160MIG.

UNSPSC 51112302 Improsulfan is a Commodity code that encompasses pharmaceutical products used in state and local healthcare and pharmacy benefit programs. The recent state and local activity under this code reflects state health agencies soliciting vendor capabilities and market intelligence regarding direct-to-manufacturer prescription fulfillment and pharmacy benefit management arrangements. The Texas Health and Human Services Commission issued an RFI in April 2026 seeking vendor responses on establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management, specifically requesting information about vendors' experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements.

The code shows limited recent activity in the posted opportunities block, with primary solicitation activity centered in Texas at the state health agency level. The Texas HHS Commission RFI posted April 3, 2026, with the same-day response deadline, represents exploratory procurement seeking vendor qualifications and market intelligence rather than a formal competitive solicitation; the state indicated intent to use vendor responses to develop detailed procurement specifications, pricing models, and implementation timelines for subsequent formal RFPs. No award values, budget ranges, set-asides, or formal evaluation criteria were specified in the RFI materials at this preliminary stage. The narrowness of recent opportunities suggests this code may see limited near-term procurement velocity, or activity may be concentrated in specialized pharmacy benefit initiatives within individual state agencies rather than distributed across multiple jurisdictions.